Latest Share Chat

SUMM.L Share News (SUMM)

SUMM.L Information

There is currently no data for SUMM

Summit Corp. forms advisory board to aid development of drug

Wed, 13th Feb 2013 13:32

Summit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD). The board will be made up of six world-renowned scientists and clinicians with expertise in the field of neuromuscular diseases, and particularly DMD."We are absolutely delighted to have brought together these eminent thought leaders in neuromuscular diseases to form a world-class Advisory Board that will support our DMD programme," commented Glyn Edwards, Chief Executive Officer of Summit. "Their expertise brings a deep insight into the disease and will provide invaluable input into future patient clinical trials to support the progression of our utrophin modulation programme, including our lead candidate SMT C1100."Shares in the company have fallen almost 30% in the year-to-date, equal to 1.88p. NR

More News

24 Feb 2016 12:35

Summit Therapeutics hails strong C-difficile findings

(ShareCast News) - Summit Therapeutics has reported that pre-clinical research into its treatment for the Clostridium difficile hospital superbug has found it to be a "novel and potent antibiotic". A peer-reviewed paper has been produced based on a study of Summit's ridinilazole versus current stand

19 Jan 2016 12:48

Summit Therapeutics gains worldwide patent protection for C-diff drug

(ShareCast News) - Summit Therapeutics has won a key patent protecting its novel antibiotic, ridinilazole, for the treatment of infections caused by the Clostridium difficile hospital superbug. The patent will grant Summit exclusivity in Europe for the use of ridinilazole in the treatment of CDI unt

19 Jan 2016 12:18

Summit Therapeutics Gets European Patent For Antibiotic Ridinilazole

22 Dec 2015 12:02

Port Erin Biopharma Continues To Look For Investments, Swings To Loss

17 Dec 2015 12:28

Summit Therapeutics Third Quarter Loss Widens As Pipeline Progresses

17 Nov 2015 12:17

Summit Therapeutics Extends Alliance With University Of Oxford

18 Sep 2015 12:50

Summit Therapeutics To Present Positive SMT19969 Data In San Diego

10 Sep 2015 11:11

Summit Therapeutics Finishes Enrolment For Phase II SMT19969 Trial

27 Aug 2015 11:48

Summit Therapeutics First Half Loss Widens As It Develops Pipeline

17 Aug 2015 12:33

Summit Therapeutics surges on positive clinical trial update

(ShareCast News) - Shares in Summit Therapeutics surged after the company said that its phase 1B clinical trial of SMT C1100 for the treatment of Duchenne muscular dystrophy met its primary objective and will now move on to a Phase 2 trial. The drug discovery and development company said half of the

14 Jul 2015 07:25

LONDON BRIEFING: Iran Nuclear Agreement Hits Oil Prices

13 Jul 2015 11:23

Summit Therapeutics Says Preclincal Data Support Its DMD Treatment

8 Jul 2015 12:04

Summit Therapeutics receives FDA fast-track decision for new antibiotic

Drug discovery and development company Summit Therapeutics has received approval from the US and Food Drug Administration (FDA) for its novel antibiotic. The FDA granted fast-track designation for the SMT19969 antibiotic which treats both duchenne muscular dystrophy and C. difficile infection (CDI).

8 Jul 2015 11:22

Summit Therapeutics Says CDI Antibiotic Given Fast Track Designation

7 Jul 2015 11:24

Latest Share Chat

SUMM.L Share News (SUMM)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Summit Corp. forms advisory board to aid development of drug

Login to your account

Quickpicks are a member only feature

Login to your account